PSB-1115

PSB-1115 is a highly selective, water-soluble small molecule antagonist of the adenosine A2B receptor. Developed by the University of Bonn, it is primarily utilized as a research tool to investigate the role of adenosine signaling in various pathologies. Preclinical evidence suggests its utility in treating inflammation, chronic pain, and fibrosis. In the context of oncology, particularly pancreatic ductal adenocarcinoma (PDAC), PSB-1115 has demonstrated the ability to inhibit tumor growth and shift the immune landscape toward an anti-tumor state by increasing CD8+ T-cell infiltration and promoting M1-like macrophage polarization.

Other names

4-(2,3,6,7-Tetrahydro-2,6-dioxo-1-propyl-1H-purin-8-yl)-benzenesulfonic acid